Edesa Biotech, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 77.83. In total, the insiders bought 2 363 647 and sold 303 639 EDSA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
77.83
Buy 2 363 647 Shares
Sell 303 639 Shares

Historical Insider Trades

Date Type Action Person Amount
Jul 02, 2024 Common Shares Buy Nijhawan Pardeep 4 015
Jun 03, 2024 Common Shares Buy Nijhawan Pardeep 4 785
May 01, 2024 Common Share Buy Nijhawan Pardeep 3 083
Apr 01, 2024 Common Shares Buy Nijhawan Pardeep 3 253
Mar 25, 2024 Common Shares Buy Nijhawan Pardeep 5 000
Mar 01, 2024 Common Shares Buy Nijhawan Pardeep 2 765
Feb 01, 2024 Common Shares Buy Nijhawan Pardeep 2 978
Jan 08, 2024 Common Shares Buy Nijhawan Pardeep 2 908
Aug 04, 2023 Common Shares Buy Lemieux Stephen 17 400
Aug 04, 2023 Common Shares Buy Brooks Michael J 93 200
Aug 04, 2023 Common Shares Buy Nijhawan Pardeep 99 300
Jul 20, 2023 Share Option (right to buy) Buy Olson Charles V 20 000
Jul 20, 2023 Share Option (right to buy) Buy Brooks Michael J 80 000
Jul 20, 2023 Share Option (right to buy) Buy Chypyha Joan 20 000
Jul 20, 2023 Share Option (right to buy) Buy Sistilli Carlo 20 000
Jul 20, 2023 Share Option (right to buy) Buy Oakes Frank R. 20 000
Jul 20, 2023 Share Option (right to buy) Buy Macdonald Sean Arthur 20 000
Jul 20, 2023 Share Option (right to buy) Buy Marshall Patrick 20 000
Jul 20, 2023 Share Option (right to buy) Buy Nijhawan Pardeep 120 000
Jul 20, 2023 Share Option (right to buy) Buy Lemieux Stephen 75 000
Jul 20, 2023 Share Option (right to buy) Buy Nijhawan Pardeep 120 000
Jul 20, 2023 Share Option (right to buy) Buy Lemieux Stephen 75 000
Jul 20, 2023 Share Option (right to buy) Buy Brooks Michael J 80 000
Jul 20, 2023 Share Option (right to buy) Buy Marshall Patrick 20 000
Jul 20, 2023 Share Option (right to buy) Buy Macdonald Sean Arthur 20 000
Click to get the best stock tips daily for free!

About Edesa Biotech, Inc.

Edesa Biotech. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chro... EDSA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT